The Heart Has Intrinsic Ketogenic Capacity that Mediates NAD + Therapy in HFpEF
Circulation Research · 09.05.2025 · 136 (10) · 1113-1130
DOI: 10.1161/circresaha.124.325550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation Research, erschienen am 09.05.2025. Verfasst von Yen Chin Koay und 16 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, School of Medical Sciences (Y.C.K., B.M., Y.H.N., X.W., Y.H., S.T., A.Y.B., B.H., P.G.B., S.L., M.L., J.F.O.), The Un…. Hauptthemen laut MEDLINE: NAD, Heart Failure, Stroke Volume, Hydroxymethylglutaryl-CoA Synthase. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has overtaken heart failure with reduced ejection fraction as the leading type of heart failure globally and is marked by high morbidity and mortality rates, yet with only a single approved pharmacotherapy: SGLT2i (sodium-glucose co-transporter 2 inhibitor). A prevailing theory for the mechanism underlying SGLT2i is nutrient deprivation signaling, of which ketogenesis is a hallmark. However, it is unclear whether the canonical ketogenic enzyme, HMGCS2 (3-hydroxy-3-methylglutaryl-coenzyme A synthase 2), plays any cardiac role in HFpEF pathogenesis or therapeutic response. METHODS: We used human myocardium, human HFpEF and heart failure with reduced ejection fraction transcardiac blood sampling, an established murine model of HFpEF, ex vivo Langendorff perfusion, stable isotope tracing in isolated cardiomyocytes, targeted metabolomics, proteomics, lipidomics, and a novel cardiomyocyte-specific conditional HMGCS2-deficient model that we generated. RESULTS: We demonstrate, for the first time, the intrinsic capacity of the human heart to produce ketones via HMGCS2. We found that increased acetylation of HMGCS2 led to a decrease in the enzyme’s specific activity. However, this was overcome by an increase in the steady-state levels of protein. Oxidized form of nicotinamide adenine dinucleotide repletion restored HMGCS2 function via deacetylation, increased fatty acid oxidation, and rescued cardiac function in HFpEF. Critically, using a conditional, cardiomyocyte-specific HMGCS2 knockdown murine model, we revealed that the oxidized form of nicotinamide adenine dinucleotide is unable to rescue HFpEF in the absence of cardiomyocyte HMGCS2. CONCLUSIONS: The canonical ketogenic enzyme, HMGCS2, mediates the therapeutic effects of the oxidized form of nicotinamide adenine dinucleotide repletion in HFpEF by restoring normal lipid metabolism and mitochondrial function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Health, School of Medical Sciences (Y.C.K., B.M., Y.H.N., X.W., Y.H., S.T., A.Y.B., B.H., P.G.B., S.L., M.L., J.F.O.), The University of Sydney, New South Wales, Australia.
- Cardiometabolic Medicine (Y.C.K., B.M., Y.H.N., X.W., Y.H., P.G.B., S.L., J.F.O.), The University of Sydney, New South Wales, Australia.
- Charles Perkins Centre (Y.C.K., B.M., Y.H.N., X.W., Y.H., B.H., P.G.B., S.L., M.L., J.F.O.), The University of Sydney, New South Wales, Australia.
- Division of Life Sciences and Medicine, Department of Cardiology, The First Affiliated Hospital of USTC (Y.C.), University of Science and Technology of China (USTC), Hefei.
- Division of Life Sciences and Medicine, School of Basic Medical Sciences (Y.C.), University of Science and Technology of China (USTC), Hefei.
- Precision Cardiovascular Laboratory (B.H., S.L.), The University of Sydney, New South Wales, Australia.
ORCID-Profile: Yen Chin Koay, Bailey McIntosh, Yann Huey Ng, Xiao Suo Wang, Yanchuang Han, Saki Tomita, Angela Yu Bai, Benjamin Hunter, Ashish Misra, Christopher M Loughrey, Paul G Bannon, Sean Lal, Aldons J Lusis, David M Kaye, Mark Larance, John F O'Sullivan
Zitieren
APA
Koay, Y. C., McIntosh, B., Ng, Y. H., Cao, Y., Wang, X. S., Han, Y., Tomita, S., Bai, A. Y., Hunter, B., Misra, A., Loughrey, C. M., Bannon, P. G., Lal, S., Lusis, A. J., Kaye, D. M., Larance, M., & O'Sullivan, J. F. (2025). The Heart Has Intrinsic Ketogenic Capacity that Mediates NAD + Therapy in HFpEF. Circulation Research, 136(10), 1113-1130. https://doi.org/10.1161/circresaha.124.325550
Vancouver
Koay YC, McIntosh B, Ng YH, Cao Y, Wang XS, Han Y, et al. The Heart Has Intrinsic Ketogenic Capacity that Mediates NAD + Therapy in HFpEF. Circulation Research. 2025;136(10):1113-1130. doi:10.1161/circresaha.124.325550
BibTeX
@article{Koay2025,
author = {Koay, Yen Chin and McIntosh, Bailey and Ng, Yann Huey and Cao, Yang and Wang, Xiao Suo and Han, Yanchuang and Tomita, Saki and Bai, Angela Yu and Hunter, Benjamin and Misra, Ashish and Loughrey, Christopher M and Bannon, Paul G and Lal, Sean and Lusis, Aldons J and Kaye, David M and Larance, Mark and O'Sullivan, John F},
title = {The Heart Has Intrinsic Ketogenic Capacity that Mediates NAD + Therapy in HFpEF},
journal = {Circulation Research},
year = {2025},
volume = {136},
number = {10},
pages = {1113--1130},
doi = {10.1161/circresaha.124.325550}
}
EUVIMED